Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Article
  • Cited by 5
  • Cited by
    Crossref Citations
    Crossref logo
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.
    Tristan, Mario Orozco, Leonardo J Steed, Antonia Ramírez-Morera, Anggie and Stone, Peter 2012. Mifepristone for uterine fibroids. Cochrane Database of Systematic Reviews,
    Orozco, Leonardo J Clarke, Jane Tristán, Mario Spies, James B Stone, Peter and Orozco, Leonardo J 2009. Cochrane Database of Systematic Reviews.
    Hanstede, Miriam Stewart, Elizabeth and Tempany, Clare 2007. MRI-Guided Focused Ultrasound Surgery. p. 111.
    Griffiths, Anthony N D'Angelo, Arianna Amso, Nazar N and Griffiths, Anthony N 2006. Cochrane Database of Systematic Reviews.
    Griffiths, A D'Angelo, A Amso, N and Griffiths, Anthony 2002. The Cochrane Database of Systematic Reviews.
    ×
  • Get access
    Add to cart USD35.00
    Check if you have access via personal or institutional login
    Log in Register

GnRH analogues in the treatment of fibroids

  • Christine P West (a1)
Extract

Uterine fibroids are estimated to affect up to 25% of women of reproductive age and are a common cause of morbidity, being associated with menstrual dysfunction, iron deficiency anaemia, pregnancy wastage and subfertility. Their pathogenesis remains unknown but their association with ovarian function and oestrogen production is undisputed and supported by their occurrence only after puberty and the shrinkage observed after the menopause. This oestrogen dependency has recently been exploited therapeutically through investigation of the use of agents that induce a hypo-oestrogenic state, the gonadotrophin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LHRH) analogues.

Copyright
COPYRIGHT: © Cambridge University Press 1993
Corresponding author
Christine P West, Department of Obstetrics and Gynaecology, University of Edinburgh, Centre for Reproductive Biology, 37 Chalmers Street, Edinburgh EH3 9EW, UK.
References
Hide All
1Smith, CJ. Hysterectomy for benign pelvic conditions. Am J Obstet Gynecol 1952; 64: 1211–20.
2Buttram, VC, Reiter, RC. Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 1981; 36: 433–45.
3West, CP. Uterine fibroids. In: Shaw, RW, Soutter, WP, Stanton, SL eds. Gynaecology. Edinburgh: Churchill Livingstone, 1992: 397–411.
4Gordon, K, Hodgen, GD. Will GnRH antagonists be worth the wait? Reprod Med Rev 1992; 1: 189–94.
5Sandow, J. Clinical application of LHRH and its analogues. Clin Endocrinol 1983; 18: 571–92.
6Fraser, MH, Baird, DT. Clinical applications of LHRH analogues. Clin Endocrinol Metab 1987; 1: 43–70.
7West, CP. LHRH analogues in the management of uterine fibroids, premenstrual syndrome and breast malignancies. Baillieres Clin Obstet Gynaecol 1988; 2: 689–709.
8West, CP, Baird, DT. Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue. Clin Endocrinol 1987; 26: 213–20.
9West, CP, Lumsden, MA, Lawson, S, Williamson, J, Baird, DT. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 1987; 48: 45–51.
10Matta, WHM, Shaw, RW, Nye, M. Long term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. Br J Obstet Gynecol 1989; 96: 200–206.
11Filicori, M, Hall, DA, Loughlin, JS, Rivier, J, Vale, W, Crowley, WF. A conservative approach to the management of uterine leiomyomata: pituitary desensitisation by a luteinizing hormone-releasing hormone analogue. Am J Obstet Gynecol 1983; 147: 726–27.
12Maheux, R, Guilloteau, C, Lemay, A, Bastide, A, Fazekas, AT. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study. Am J Obstet Gynecol 1985; 152: 1034–38.
13Healy, DL, Lawson, SR, Abbott, M, Baird, DT, Fraser, HM. Towards removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase. J Clin Endocrinol Metab 1986; 63: 619–25.
14Maheux, R, Lemay, A, Merat, P. Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas. Fertil Steril 1987; 7: 229–33.
15Friedman, AJ, Barbieri, RL, Benacerraf, BR, Schiff, I. Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist. Fertil Steril 1987; 48: 560–64.
16Perl, V, Marquez, J, Schally, AV et al. Treatment of leiomyomata uteri with D-Trp-6-luteinizing hormone-releasing hormone. Fertil Steril 1987; 48: 383–89.
17Kessel, B, Liu, J, Berga, S, Yen, SSC. Treatment of uterine fibroids with agonist analogues of gonadotropin-releasing hormone. Fertil Steril 1988; 49: 538–41.
18Andreyko, JL, Blumenfeld, Z, Marshall, A, Monroe, SE, Hricak, H, Jaffe, RB. Use of an agonist analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: Assessment of magnetic resonance imaging. Am J Obstet Gynecol 1988; 158: 903–10.
19Golan, A, Bukovsky, I, Schneider, D, Ron-El, R, Herman, A, Caspi, E. D-Trp-6 luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas. Fertil Steril 1989; 52: 406–11.
20Lettrie, GS, Coddington, CG, Winkel, CA, Shawker, TH, Loriaux, DL, Collins, RL. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up. Fertil Steril 1989; 51: 951–56.
21Schlaff, WD, Zernouni, EA, Huth, J, Chan, J, Damewood, MD, Rock, JA. A placebo-controlled trial of a depot gonadotropin-releasing hormone analog (leuprolide) in the treatment of uterine leiomyomata. Obstet Gynecol 1989; 74: 856–62.
22Friedman, AJ, Hoffman, DI, Comite, F, Browneller, RW, Miller, JD. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The leuprolide study group. Obstet Gynecol 1991; 77: 720–25.
23Vollenhoven, BJ, Shekleton, P, McDonald, J, Healy, DL. Clinical predictors of buserelin acetate treatment of uterine fibroids: a prospective study of 40 women. Fertil Steril 1990; 54: 1032–38.
24Costanini, S, Anserini, P, Valenzana, M, Remorgida, V, Venturi, PL, De Cecco, L. Luteinizing hormone-releasing hormone analogue therapy of uterine fibroids: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot. Eur J Obstet Gynecol Reprod Biol 1990; 37: 63–69.
25Watanabe, Y, Nakamura, G, Matsuguchi, H, Nozaki, M, Sano, M, Nakano, H. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women. Fertil Steril 1992; 58: 66–71.
26West, CP, Lumsden, MA. Fibroids and menorrhagia. Baillieres Clin Obstet Gynaecol 1989; 3: 357–74.
27Zawin, M, McCarthy, S, Scoutt, L, Lange, R, Lavy, G, Vulte, J, Comite, F. Monitoring therapy with a gonadotropin-releasing hormone analogue: utility of MR imaging. Radiology 1990; 175: 503–506.
28Williams, IA, Shaw, RW. Effects of nafarelin on uterine fibroids measured by ultrasound and magnetic resonance imaging. Eur J Obstet Gynecol Reprod Biol 1990; 34: 111–17.
29Friedman, AJ, Daly, M, Juneau-Norcross, M, Rein, MS. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist. Fertil Steril 1991; 58: 413–15.
30Maheux, R, Lemay, A, Blanchet, P, Friede, J, Pratt, X. Maintained reduction of uterine leiomyomata following addition of hormone replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study. Hum Reprod 1991; 6: 500–505.
31Fogelman, I. Gonadotropin-releasing hormone agonists and the skeleton. Fertil Steril 1992; 57: 715–24.
32Matta, WH, Shaw, RW, Hesp, R, Katz, D. Hypogonadism induced by luteinizing hormone releasing hormone agonist analogues: effects on bone density in premenopausal women. Br Med J 1987; 294: 1523–24.
33Dawood, MY, Lewis, V, Ramos, J. Cortical and trabecular bone mineral content in women with endometriosis: effects of gonadotropin-releasing hormone agonist and danazol. Fertil Steril 1989; 52: 21–26.
34Johansen, JS, Riis, BJ, Hassanger, C, Moen, M, Jacobson, J, Christiansen, C. The effect of a gonadotropin-releasing hormone agonist analogue (nafarelin) on bone metabolism. J Clin Endocrinol Metab 1988; 67: 701–706.
35Friedman, AJ. Vaginal haemorrhage associated with degenerating submucous leiomyomata during leuprolide acetate treatment. Fertil Steril 1989; 52: 152–54.
36Thorp, JM, Katz, VL. Submucous myomas treated with gonadotropin-releasing hormone agonist and resulting in vaginal haemorrhage – a case report. J Reprod Med 1991; 36: 625–26.
37Healy, DL, Vollenhoven, BJ. The role of GnRH agonists in the treatment of uterine fibroids. Br J Obstet Gynaecol 1992; 99(supp 7): 23–26.
38Chipato, T, Vollenhoven, BJ, Buckler, HM, Healy, DL. Pelvic pain complicating LHRH agonist treatment of fibroids. Aust N Z J Obstet Gynaecol 1991; 31: 383–84.
39Ellenbogen, A, Shulman, A, Libai, Y, Jaschevatzky, O, Anderman, S, Grunstein, S. Complication of triptorelin treatment for uterine myomas. Lancet 1989; ii: 167–68.
40Lee, MJ, Kazer, RR. Massive ascites after leuprolide acetate administration for the treatment of leiomyomata uteri. Fertil Steril 1991; 58: 416–18.
41Lawson, TL, Albarelli, N. Diagnosis of gynecologic pelvic masses by gray scale ultrasonography: analysis of specificity and accuracy. Am J Roentgenol 1977; 128: 1003–1006.
42Walsh, JW, Taylor, KJW, Wasson, JR McL, Schwartz, PE, Rosenfield, AT. Gray scale ultrasound in 204 proven gynecological masses: accuracy and specific diagnostic criteria. Radiology 1979; 130: 391–97.
43Hricak, H, Tscholakoff, D, Heinrichs, L et al. Uterine leiomyomas: correlation of MR, histopathologic findings and symptoms. Radiology 1986; 158: 385–91.
44Fedele, L, Bianchi, S, Dorta, M, Brioschi, D, Zanotti, F, Vercellini, P. Transvaginal ultrasonography versus hysteroscopy in the diagnosis of uterine submucous myomas. Obstet Gynecol 1991; 77: 745–48.
45Leibsohn, S, d'Ablaing, G, Mishell, DR, Schlaerth, JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 1990; 162: 968–74.
46Meyer, WR, Mayer, AR, Diamond, MP, Carcangiu, ML, Schwartz, PE, DeCherney, AH. Unsuspected leiomyosarcoma: treatment with a gonadotropin-releasing hormone analogue. Obstet Gynecol 1990; 75: 529–32.
47Corscaden, JA, Singh, BP. Leiomyosarcoma of the uterus. Am J Obstet Gynecol 1958; 75: 149–53.
48Loong, PL, Wong, FWS. Uterine leiomyosarcoma diagnosed during treatment with agonist of luteinizing hormone-releasing hormone for presumed uterine fibroid. Fertil Steril 1990; 54: 530–31.
49Corson, SL, Brooks, PG. Resectoscopic myomectomy. Fertil Steril 1991; 55: 1041–44.
50Hackenberg, R, Gesenhues, T, Deichert, U, Duda, V, Schmidt-Rhode, P, Schulz, KD. The response of GnRH agonist treatment can be predicted in most cases after one month. Eur J Obstet Gynecol Reprod Biol 1992; 45: 125–29.
51Seki, K, Hoshihara, T, Nagatu, I. Leiomyosarcoma of the uterus: ultrasonography and serum lactate dehydrogenase level. Gynecol Obstet Invest 1992; 33: 114–18.
52Matta, WHM, Stabile, I, Shaw, RW, Campbell, S. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist buserelin. Fertil Steril 1988; 49: 1083–85.
53Crow, J. Uterine fibroids: histological features. In: Shaw, RW ed. Uterine fibroids: time for review. Camforth, UK: The Parthenon Publishing Group, 1992: 21–33.
54Upadhyaya, MB, Doody, MC, Googe, PB. Histopathological changes in leiomyomata treated with leuprolide acetate. Fertil Steril 1990; 54: 811–14.
55Uemura, T, Mori, J, Yoshimura, Y, Minaguchi, H. Treatment effects of GnRH agonists on the binding of estrogen and progesterone and the histological findings of uterine leiomyomas. Asia Oceania J Obstet Gynecol 1991; 17: 315–20.
56Wilson, EA, Yang, F, Rees, ED. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet Gynecol 1980; 55: 20–24.
57Soules, MR, McCarty, KS. Leiomyomas: steroid receptor content. Variation within normal menstrual cycles. Am J Obstet Gynecol 1982; 143: 6–11.
58Lumsden, MA, West, CP, Hawkins, TA, Bramley, TA, Rumgay, L, Baird, DT. The binding of steroids to myometrium and leiomyomata (fibriods) in women treated with the gonadotrophin-releasing hormone agonist, Zoladex (ICI 118640). J Endocrinol 1989; 121: 389–96.
59Rein, MS, Friedman, AJ, Stuart, JM, MacLaughlin, DT. Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertil Steril 1990; 53: 1018–23.
60Farber, M, Conrad, S, Heinrichs, W, Herrmann, W. Estradiol binding by fibroid tumours and normal myometrium. Obstet Gynecol 1972; 40: 479–86.
61Neuman, M, Langer, R, Golan, A, Bukovsky, I, Caspi, E, Koch, Y. Gonadotropin-releasing hormone (GnRH) action on uterine leiomyomata is not mediated by uterine GnRH receptors. Fertil Steril 1991; 56: 364–66.
62Deuel, TF. Polypeptide growth factors: roles in normal and abnormal cell growth. Ann Rev Cell Biol 1987; 3: 445–92.
63Hofman, GE, Rao, CHV, Barrows, GH, Schutz, GS, Sanfilippo, JS. Binding sites for epidermal growth factor in human uterine tissue and leiomyomas. J Clin Endocrinol Metab 1984; 58: 880–84.
64Lumsden, MA, West, CP, Bramley, TA, Rumgay, L, Baird, DT. The binding of epidermal growth factor to the human uterus and leiomyomata in women rendered hypo-oestrogenic by continuous administration of an LHRH agonist. Br J Obstet Gynaecol 1988; 95: 1299–1304.
65Tommola, P, Pekonen, F, Rutaran, EM. Binding of epidermal growth factor and insulin-like growth factor I in human myometrium and leiomyoma. Obstet Gynecol 1989; 74: 658–62.
66Rein, MS, Friedman, AJ, Pandian, MR, Heffner, LJ. The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist. Obstet Gynecol 1990; 76: 388–94.
67Dicker, RC, Greenspan, JR, Strauss, LT et al. Complications of abdominal hysterectomy among women of reproductive age in the United States. The collaborative review of sterilisation. Am J Obstet Gynecol 1982; 144: 841–48.
68Vessey, MP, Villard Mackintosh, L, Coulter, A, Yeates, D. The epidemiology of hysterectomy: findings in a large cohort study. Br J Obstet Gynaecol 1992; 99: 402–407.
69Lumsden, MA, West, CP, Baird, DT: Goserelin therapy before surgery for uterine fibroids. Lancet; i: 36–37.
70Lumsden, MA, Thomas, E, Coutts, JRT, West, CP, Baird, T. Goserelin pretreatment facilitates abdominal hysterectomy for the removal of uterine leiomyomata (fibroids). Gynecol Endocrinol 1990; 4(suppl 2):41.
71West, CP, Lumsden, MA, Baird, DT. Goserelin (Zoladex®) in the treatment of fibroids. Br J Obstet Gynaecol 1992; 99(suppl 7): 27–30.
72Stovall, TG, Ling, FW, Henry, LC, Woodruff, R. A randomised trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol 1991; 164: 1420–23.
73Fedele, L, Bianchi, S, Baglioni, A, Arcaini, L, Marchini, M, Bocciolone, L. Intranasal buserelin versus surgery in the treatment of uterine leiomyomata: long-term follow-up. Eur J Obstet Gynecol Reprod Blol 1991; 38: 53–57.
74Candiani, GB, Vercellini, P, Arcaini, L, Bianchi, S, Candiani, M. Use of goserelin depot, a gonadotropin-releasing hormone agonist for the treatment of menorrhagia and severe anaemia in women with leiomyomata uteri. Acta Obstet Gynaecol Scand 1990; 69: 413–15.
75Verkauf, BS. Myomectomy for fertility enhancement and preservation. Fertil Steril 1992; 58: 1–15.
76Gardner, RL, Shaw, RW. GnRH agonists and blood loss at surgery. In: Shaw, RW ed. Uterine fibroids: time for review. Carnforth, UK: The Parthenon Publishing Group, 1992: 123–34.
77Fedele, L, Vercellini, P, Bianchi, S, Brioschi, D, Dorta, M. Treatment with GnRH agonists before myomectomy and the risk of short term myoma recurrence. Br J Obstet Gynaecol 1990; 97: 393–96.
78Friedman, AJ, Rein, MS, Harrison-Atlas, D, Garfield, JM, Doubilet, PM. A randomised, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. Fertil Steril 1989; 52: 728–33.
79Friedman, AJ, Daly, M, Juneau-Norcross, M, Fine, C, Rein, MS. Recurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placebo. Fertil Steril 1992; 59: 205–208.
80Neuwirth, RS. Hysteroscopic management of symptomatic submucus uterine fibroids. Obstet Gynecol 1983; 62: 509–11.
81Donnez, J, Schrurs, B, Gillerot, S, Sandow, J, Clerckx, F. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril 1989; 51: 947–50.
82Donnez, J, Gillerot, S, Bourgonjon, D, Clerckx, F, Nisolle, M. Neodymium: YAG laser hysteroscopy in large submucous fibroids. Fertil Steril 1990; 54: 999–1003.
83Donnez, J, Nisolle, M, Grandjean, P, Gillerot, S, Clerckx, F. The place of GnRH agonists in the treatment of endometriosis and fibroids by advanced hysteroscopic techniques. Br J Obstet Gynaecol 1991; 99(suppl 7): 31–33.
84Derman, SG, Rehnstrom, J, Neuwirth, RS. The long-term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol 1991; 77: 591–94.
85Semm, K, Mettler, L. Technical progress in pelvic surgery via operative laparoscopy. Am J Obstet Gynecol 1980; 138: 121–27.
86Dubuisson, JB, Lecuru, F, Foulot, H, Mandelbrot, L, Aubriot, FX, Mouly, M. Myomectomy by laparoscopy; a preliminary report of 43 cases. Fertil Steril 1991; 56: 827–30.
87Goldfarb, HA. Nd:YAG laser laparoscopic coagulation of symptomatic myomas. J Reprod Med 1992; 37: 636–38.
88Friedman, AJ. Treatment of leiomyomata uteri with short-term leuprolide followed by oestrogen-progestin hormone replacement therapy for two years: a pilot study. Fertil Steril 1989; 51: 526–28.
89Maheux, R, Lemay, A. Treatment of perimenopausal women: potential long-term therapy with a depot GnRH agonist combined with hormone replacement therapy. Br J Obstet Gynaecol 1992; 99 (suppl 7): 13–17.
90Lumsden, MA, West, CP, Baird, DT: Tamoxifen prolongs luteal phase in premenopausal women but has no effect on the size of uterine fibroids. Clin Endocrinol 1989; 31: 335–43.
91Lumsden, MA, West, CP, Hillier, H, Baird, DT. Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin) – a lack of shrinkage of uterine fibroids. Fertil Steril 1989; 52: 924–29.
92McDonald, CC, Stewart, HJ. (Scottish Breast Cancer Committee.) Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J 1991; 303: 435–37.
93Turner, RT, Wakley, GK, Hannon, KS, Bell, NH: Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 1988; 122: 1146–50.
94Turkin, S, Siris, E, Seldin, D, Laster, E, Hyman, G, Lindsay, R. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 1989; 81: 1086–88.
95Lindsay, R, Hart, DM, Purdie, D, Ferguson, MM, Clark, AS, Kraszewski, A. Comparative effects of oestrogen and progestogen on bone loss in postmenopausal women. Clin Sci Mol Med 1978; 54: 193–95.
96Mandel, FP, Davidson, BJ, Erlik, Y, Judd, HL, Meldrum, DR. Effects of progestins on bone metabolism in postmenopausal women. J Reprod Med 1982; 27: 511–14.
97Goldzieher, JW, Maqueo, M, Ricard, L, Aquilar, JA, Canales, E. Induction of degenerative changes in uterine myomas by high dose progestin therapy. Am J Obstet Gynecol 1966; 96: 1078–87.
98Friedman, AJ, Barbieri, RL, Doubilet, PM, Fine, C, Schiff, I. A randomised double blind trial of a gonadotrophin releasing hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988; 49: 404–409.
99West, CP, Lumsden, MA, Millier, H, Sweeting, V, Baird, DT. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids. Hum Reprod 1992; 7: 328–32.
100Benagiano, G, Morini, A, Aleandri, F et al. Sequential Gn-RH superagonist and medroxyprogesterone acetate treatment of uterine leiomyomata. Int J Obstet Gynecol 1990; 33: 333–43.
101Bayard, F, Damilano, S, Robel, P, Baulieu, EE. Cytoplasmic and nuclear oestradiol and progesterone receptors in human endometrium. J Clin Endocrinol Metab 1978; 46: 635–48.
102Tseng, L, Gurpide, E. Effect of progestins on estradiol receptors in human endometrium. J Clin Endocrinol Metab 1975; 41: 402–404.
103Nakamura, Y, Yoshimura, Y, Yamada, H, Ubukata, Y, Ando, M, Suzuki, M. Treatment of leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of non-surgical management in selected perimenopausal women. Fertil Steril 1991; 55: 900–905.
104Gardner, RL, Shaw, RW. Cornual fibroids: a conservative approach to restoring tubai patency using a gonadotropin-releasing hormone agonist (goserelin) with successful pregnancy. Fertil Steril 1989; 52: 332–34.
105Naether, O, Diedrich, K. Intrauterine pregnancy with uterine myoma after downregulation with GnRH analogues. Geburtshilfe Frauenheilkd 1992; 52: 121–22.
106Volpe, A, Adamo, R, Coukos, G, Silferi, M, Artini, PG, Genazzani, AR. Pregnancy following regression of uterine submucosal leiomyoma with GnRH therapy: a case report. Eur J Obstet Gynecol Reprod Biol 1991; 39: 223–25.
107Blumenfeld, Z, Enat, R, Brandes, JM, Baruch, Y. Gonadotropin-releasing hormone analogues for dysfunctional bleeding in women after liver transplantation: a new application. Fertil Steril 1992; 57: 1121–23.
108Shikora, SA, Niloff, JM, Bistrian, BR, Forse, RA, Blackburn, GL. Relationship between obesity and leiomyomata. Nutrition 1991; 7: 251–55.
109Reiter, RC, Wagner, PL, Gambone, JC. Routine hysterectomy for asymptomatic uterine fibroids: a reappraisal. Obstet Gynecol 1992; 79: 481–84.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Reproductive Medicine Review
  • ISSN: 0962-2799
  • EISSN: 1469-9028
  • URL: /core/journals/reproductive-medicine-review
Please enter your name
Please enter a valid email address
Who would you like to send this to? *

CAPTCHA *

Skip to the audio challenge
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 5 *
Loading metrics...

Abstract views

Total abstract views: 65 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 12th June 2018. This data will be updated every 24 hours.

Cancel
Confirm
×